Neuro Oncol. 2024 Jun 10. pii: noae105. [Epub ahead of print]
Min Hye Noh,
Jin Muk Kang,
Alexandra A Miller,
Grace Nguyen,
Minxin Huang,
Ji Seon Shim,
Alberto J Bueso-Perez,
Sara A Murphy,
Kimberly A Rivera-Caraballo,
Yoshihiro Otani,
Eunju Kim,
Seung-Hee Yoo,
Yuanqing Yan,
Yeshavanth Banasavadi-Siddegowda,
Hiroshi Nakashima,
E Antonio Chiocca,
Balveen Kaur,
Zhongming Zhao,
Tae Jin Lee,
Ji Young Yoo.
BACKGROUND: The FDA approval of oncolytic herpes simplex-1 virus (oHSV) therapy underscores its therapeutic promise and safety as a cancer immunotherapy. Despite this promise, the current efficacy of oHSV is significantly limited to a small subset of patients largely due to the resistance in tumor and tumor microenvironment (TME).
METHODS: RNA sequencing (RNA-Seq) was used to identify molecular targets of oHSV resistance. Intracranial human and murine glioma or breast cancer brain metastasis (BCBM) tumor-bearing mouse models were employed to elucidate the mechanism underlying oHSV therapy-induced resistance.
RESULTS: Transcriptome analysis identified IGF2 as one of the top secreted proteins following oHSV treatment. Moreover, IGF2 expression was significantly upregulated in 10 out of 14 recurrent GBM patients after treatment with oHSV, rQNestin34.5v.2 (71.4%) (p=0.0020) (ClinicalTrials.gov, NCT03152318). Depletion of IGF2 substantially enhanced oHSV-mediated tumor cell killing in vitro and improved survival of mice bearing BCBM tumors in vivo. To mitigate the oHSV-induced IGF2 in the TME, we constructed a novel oHSV, oHSV-D11mt, secreting a modified IGF2R domain 11 (IGF2RD11mt) that acts as IGF2 decoy receptor. Selective blocking of IGF2 by IGF2RD11mt significantly increased cytotoxicity, reduced oHSV-induced neutrophils/PMN-MDSCs infiltration, and reduced secretion of immune suppressive/proangiogenic cytokines, while increased CD8+cytotoxic T lymphocytes (CTLs) infiltration, leading to enhanced survival in GBM or BCBM tumor-bearing mice.
CONCLUSION: This is the first study reporting that oHSV-induced secreted IGF2 exerts a critical role in resistance to oHSV therapy, which can be overcome by oHSV-D11mt as a promising therapeutic advance for enhanced viro-immunotherapy.
Keywords: Glioblastoma (GBM); Insulin-like growth factor 2 (IGF2); Insulin-like growth factor-1 receptor (IGF1R); Oncolytic herpes simplex virus-1 (oHSV); Tumor microenvironment (TME)